| Followers | 52 |
| Posts | 14334 |
| Boards Moderated | 0 |
| Alias Born | 06/15/2014 |
Tuesday, July 09, 2024 1:46:16 AM
Thanks for all the info Kiwi. Been a long busy day so I will have to do some more DD on this one but it appears to be promising. The fact that the drug does not have the ejection fraction problem is important in my books. This could be another CYTK. My one worry is that it has had quite a sunup in 2024 already and hopefully not everything is priced in yet.
Recent EWTX News
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:49:16 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/23/2026 08:10:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 08:07:02 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 08:06:20 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 04/01/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/27/2026 08:41:21 PM
- Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up • PR Newswire (US) • 03/10/2026 11:00:00 AM
- Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026 • PR Newswire (US) • 03/04/2026 01:00:00 PM
- Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference • PR Newswire (US) • 03/03/2026 01:00:00 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 03/02/2026 02:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 01:05:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:00:52 PM
- Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs • PR Newswire (US) • 02/26/2026 01:00:00 PM
- Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 • PR Newswire (US) • 02/05/2026 01:00:00 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 02/02/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 06:34:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/21/2026 09:05:10 PM
- Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 • PR Newswire (US) • 01/13/2026 01:00:00 PM
- Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 • PR Newswire (US) • 01/06/2026 01:00:00 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 01/05/2026 01:00:00 PM
- Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy • PR Newswire (US) • 12/24/2025 01:00:00 PM
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules • PR Newswire (US) • 12/02/2025 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/25/2025 12:06:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 10:07:45 PM
